Physician profile
James Chanez
NPI 1093755316
$3,971.95
in general payments reported to CMS, 2019-2025
35 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $414 · 2021: $600 · 2022: $715 · 2023: $526 · 2024: $303 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $812.42 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $650.10 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $383.36 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $285.31 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $232.43 | 2021-2025 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $230.01 | 2019-2022 | |
| Pfizer INC. | $164.53 | 2019-2025 | |
| Inspire Medical Systems, INC. | $145.29 | 2024 | Inspire |
| Therapeuticsmd, INC. | $114.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.86 | 2022 | |
| Mylan Specialty L.P. | $97.20 | 2023-2024 | Yupelri |
| Glaxosmithkline, LLC. | $76.26 | 2019-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $70.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $70.32 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.78 | 2019-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $56.15 | 2019-2021 | |
| Sanofi Pasteur INC. | $44.26 | 2019-2020 | |
| Amarin Pharma, INC. | $31.99 | 2019-2020 | |
| Antares Pharma, INC. | $28.97 | 2019-2022 | |
| Grt US Holding, INC. | $28.90 | 2022 | |
| Merck Sharp & Dohme LLC | $27.41 | 2019 | |
| Sumitomo Pharma America, INC. | $25.98 | 2024 | Gemtesa |
| Exact Sciences Corporation | $24.23 | 2025 | Cologuard Collection Kit |
| Pylant Medical | $23.92 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.45 | 2019 | |
| Nabriva Therapeutics, Plc | $20.03 | 2021 | |
| Abbott Laboratories | $19.33 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.95 | 2020 | |
| Shire North American Group INC | $16.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.49 | 2025 | Zoryve |
| Genentech USA, INC. | $15.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.30 | 2023 | Quviviq |
| Optinose US, INC. | $11.79 | 2019 | |
| Allergan, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chanez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.